One Rare Warfarin Resistance Case and Possible Mechanism Exploration

References

• Pengo V, Denas G, Zoppellaro G, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood. 2018;132(13):1365–1371. doi:10.1182/blood-2018-04-848333
   PubMed Web of Science ®Google Scholar
• John WE, Stuart JC, Brueckmann M, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013;396(13):1206–1220. doi:10.1056/NEJMoa1300615
   Google Scholar
• Ageno W, Gallus AS, Wittkowsky A, et al. Oral anticoagulant therapy—antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141(2):e44–e88. doi:10.1378/chest.11-2292
   Web of Science ®Google Scholar
• Voora D, McLeod HL, Eey C, Gage BF. The pharmacogenetics of coumarin therapy. Pharmacogenomics. 2005;6(5):503–513. doi:10.2217/14622416.6.5.503
   PubMed Web of Science ®Google Scholar
• Shen AY, Yao JF, Brar SS, Jorgensen MB, Chen W. Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. J Am Coll Cardiol. 2007;50(4):309–315. doi:10.1016/j.jacc.2007.01.098
   PubMed Web of Science ®Google Scholar
• Dang MT, Hambleton J, Kayser SR. The influence of ethnicity on warfarin dosage requirement. Ann Pharmacother. 2005;39(6):1008–1012. doi:10.1345/aph.1E566
   PubMed Web of Science ®Google Scholar
• Fohner AE, Robinson R, Yracheta J, et al. Variation in genes controlling warfarin disposition and response in American Indian and Alaska Native people: CYP2C9, VKORC1, CYP4F2, CYP4F11, GGCX. Pharmacogenet Genomics. 2015;25(7):343–353. doi:10.1097/FPC.0000000000000143
   PubMed Web of Science ®Google Scholar
• Limdi NA, Wadelius M, Cavallari L, et al. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood. 2010;115(18):3827–3834. doi:10.1182/blood-2009-12-255992
   PubMed Web of Science ®Google Scholar
• Lefrere JJ, Horellou MH, Conard J, Samama M. Proposed classification of resistance to oral anticoagulant therapy. J Clin Pathol. 1987;40(2):242. doi:10.1136/jcp.40.2.242-c
   PubMed Web of Science ®Google Scholar
• Osinbowale O, Al Malki M, Schade A, Bartholomew JR. An algorithm for managing warfarin resistance. Cleve Clin J Med. 2009;76(12):724–730. doi:10.3949/ccjm.76a.09062
   PubMed Web of Science ®Google Scholar
• Loebstein R, Dvoskin I, Halkin H, et al. A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance. Blood. 2007;109(6):2477–2480. doi:10.1182/blood-2006-08-038984
   PubMed Web of Science ®Google Scholar
• Yuan HY, Chen JJ, Lee MT, et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter- ethnic differences in warfarin sensitivity. Hum Mol Genet. 2005;14(13):1745–1751. doi:10.1093/hmg/ddi180
   PubMed Web of Science ®Google Scholar
• Aklillu E, Leong C, Loebstein R, Halkin H, Gak E. VKORC1 Asp36Tyr warfarin resistance marker is common in Ethiopian individuals. Blood. 2008;111(7):3903–3904. doi:10.1182/blood-2008-01-135863
   PubMed Web of Science ®Google Scholar
• Sabol BJ, Basa RR, Wilkins CE. Malabsorption-associated warfarin resistance. Am J Health Syst Pharm. 2009;66(17):1548–1553. doi:10.2146/ajhp080477
   PubMed Web of Science ®Google Scholar
• Bodin L, Perdu J, Diry M, et al. Multiple genetic alterations in vitamin K epoxide reductase complex subunit 1 gene (VKORC1) can explain the high dose requirement during oral anticoagulation in humans. J Thromb Haemost. 2008;6(8):1436–1439. doi:10.1111/j.1538-7836
   PubMed Web of Science ®Google Scholar
• Haiying WANG, Zhicheng JIN, Congjian LI, et al. A case report of warfarin resistance in a patient with pulmonary embolism and literature review. Chin J Cardiol. 2004;32(11):1039–1040.
   Google Scholar
• Nikkila EA, Pelkonen R. Serum lipid-reducing agents and anticoagulant requirement. Lancet. 1963;1(7276):332. doi:10.1016/S0140-6736(63)92283-9
   Google Scholar
• Hata M, Shiono M, Akiyama K1, et al. Incidence of drug interaction when using proton pump inhibitor and warfarin according to cytochrome P450 2C19 (CYP2C19) genotype in Japanese. Thorac Cardiovasc Surg. 2015;63(1):45–50. doi:10.1055/s-0034-1383814
   PubMed Web of Science ®Google Scholar
• Mott FE, Murphy S, Hunt V. Ciprofloxacin and warfarin. Ann Intern Med. 1989;111(6):542–543. doi:10.7326/0003-4819-111-6-542_2
   PubMed Web of Science ®Google Scholar
• Kamada AK. Possible interaction between ciprofloxacin and warfarin. DICP Ann Pharmacother. 1990;24(1):27–28. doi:10.1177/106002809002400106
   PubMedGoogle Scholar
• Health Canada. Fluoroquinolones and warfarin: suspected interaction. Can Adverse React News. 2004;14(3):1–2. doi:10.2165/00128415-200410100-00003
   Google Scholar
• Chock AWY, Stading JA. Indeterminable international normalized ratio with concurrent use of warfarin and gatifloxacin. Am J Health Syst Pharm. 2006;63(16):1539–1542. doi:10.2146/ajhp060021
   PubMed Web of Science ®Google Scholar
• Jones CB, Fugate SE. Levofloxacin and warfarin interaction. Ann Pharmacother. 2002;36(10):1554–1557. doi:10.1345/aph.1C074
   PubMed Web of Science ®Google Scholar
• Ieiri I, Tainaka H, Morita T, et al. Catalytic activity of three variants (Ile, Leu, and Thr) at amino acid residue 359 in human CYP2C9 gene and simultaneous detection using single-strand conformation polymorphism analysis. Ther Drug Monit. 2000;22(3):237–244. doi:10.1097/00007691-200006000-00001
   PubMed Web of Science ®Google Scholar
• D’Ambrosio RL, D’Andrea G, Cafolla A, et al. A new vitamin K epoxide reductase complex subunit-1 (VKORC1) mutation in a patient with decreased stability of CYP2C9 enzyme. J Thromb Haemost. 2007;5(1):191–193. doi:10.1111/j.1538-7836.2006.02261.x
   PubMed Web of Science ®Google Scholar
• Rettie AE, Tai G. The pharmacogenomics of warfarin: closing in on personalized medicine. Molec Interve. 2006;6(4):223–227. doi:10.1124/mi.6.4.8
   PubMed Web of Science ®Google Scholar
• Rost S, Fregin A, Ivaskevicius V, et al. Mutations in the VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature. 2004;427(6974):537–541. doi:10.1038/nature02214
   PubMed Web of Science ®Google Scholar
• Kurnik D, Qasim H, Sominsky S, et al. Effect of the VKORC1 D36Y variant on warfarin dose requirement and pharmacogenetic dose prediction. Thromb Haemost. 2012;108(4):781–788. doi:10.1160/TH12-03-0151
   PubMed Web of Science ®Google Scholar
• Mitchell C, Gregersen N, Krause A. Novel CYP2C9 and VKORC1 gene variants associated with warfarin dosage variability in the South African black population. Pharmacogenomics. 2011;12(7):953–963. doi:10.2217/pgs.11.36
   PubMed Web of Science ®Google Scholar
• Isabel Anton A, Cerezo-Manchado JJ, Padilla J, et al. Novel associations of VKORC1 variants with higher acenocoumarol requirements. PLoS One. 2013;8(5):e644469. doi:10.1371/journal.pone.0064469
   Web of Science ®Google Scholar
• Kimura R, Miyashita K, Kokubo Y, et al. Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients. Thromb Res. 2007;120(7):181–186. doi:10.1016/j.thromres.2006.09.007
   PubMedGoogle Scholar
• Stromich JJ, Weber AK, Mirzaei YR, et al. New adjuvants to enhance anticoagulant activity of warfarin. Bioorg Med Chem Lett. 2010;20(5):1928–1932. doi:10.1016/j.bmcl.2010.01.123
   PubMedGoogle Scholar
• Vanakker OM, De Coen K, Costrop L, et al. Functional polymorphism in gamma-glutamylcarboxylase is a risk factor for severe neonatal hemorrhage. J Pediatr. 2011;159(2):347–349. doi:10.1016/j.jpeds.2011.04.044
   PubMed Web of Science ®Google Scholar
• Wadelius M, Chen LY, Downes K, et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J. 2005;5(4):262–270. doi:10.1038/sj.tpj.6500313
   PubMed Web of Science ®Google Scholar
• Rieder MJ, Reiner AP, Rettie AE. Gamma-glutamyl carboxylase (GGCX) tagSNPs have limited utility for predicting warfarin maintenance dose. J Thromb Haemost. 2007;5(11):2227–2234. doi:10.1111/j.1538-7836.2007.02744.x
   PubMed Web of Science ®Google Scholar
• Weston BW, Monahan PE. Familial deficiency of vitamin K-dependent clotting factors. Haemophilia. 2008;14(6):1209–1213. doi:10.1111/j.1365-2516.2008.01853.x
   PubMed Web of Science ®Google Scholar
• Schelleman H, Brensinger CM, Chen J, et al. New genetic variant that might improve warfarin dose prediction in African Americans. Br J Clin Pharmacol. 2010;70(3):393–399. doi:10.1111/j.1365-2125.2010.03709.x
   PubMed Web of Science ®Google Scholar
• XiayizhaKamali M, Yang Y-C, Yang Y-C, et al. Association of GGCX gene polymorphism with warfarin dose in atrial fibrillation population in Xinjiang. Lipids Health Dis. 2013;12:149–154. doi:10.1186/1476-511X-12-149
   PubMed Web of Science ®Google Scholar
• McDonald MG, Rieder MJ, Nakano M, Hsia CH, Rettie AE. Cyp4F2 is a vitamin K1 oxidase: an explanation for altered warfarin dose in carriers of the V433m variant. Mol Pharmacol. 2009;75(6):1337–1346. doi:10.1124/mol.109.054833
   PubMed Web of Science ®Google Scholar
• Caldwell MD, Awad T, Johnson JA, et al. CYP4F2 genetic variant alters required warfarin dose. Blood. 2008;111(8):4106–4112. doi:10.1182/blood-2007-11-122010
   PubMed Web of Science ®Google Scholar
• Sagrieya H, Berube C, Wen A, et al. Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9. Pharmacogenet Genomics. 2010;20(7):407–413. doi:10.1097/FPC.0b013e328338bac2
   PubMed Web of Science ®Google Scholar
• Borgiani P, Ciccacci C, Forte V, et al. CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population. Pharmacogenomics. 2009;10(2):261–266. doi:10.2217/14622416.10.2.261
   PubMed Web of Science ®Google Scholar
• Takeuchi F, McGinnis R, Bourgeois S, et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet. 2009;5(3):e1000433. doi:10.1371/journal.pgen.1000433
   PubMed Web of Science ®Google Scholar
• Klein TE, Altman RB, Eriksson N, et al; International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009;360(8):753–764. doi:10.1056/NEJMoa0809329
   PubMed Web of Science ®Google Scholar